Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry" (INOCAIT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05164640 |
|
Recruitment Status :
Recruiting
First Posted : December 21, 2021
Last Update Posted : February 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Prospective, interventional, multicentre, non-randomized, single-arm open-label study that aims to enroll 200 consecutive patients with suspected chronic ischemic heart disease in the absence of obstructive coronary artery disease (INOCA) at clinically indicated coronary angiography in 3 Italian centers.
During coronary angiography, these patients will be simultaneously subjected to a functional and coronary physiology study (according to the methods reported below):
- Functional evaluation with fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), Resting Full-Cycle Ratio (RFR) of angiographic stenosis> 50%;
- In the presence of coronary angiographic stenosis <50% or> 50% but in the presence of a negative functional assessment (FFR> 0.80 and iFR / RFR> 0.90), coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be measured. IMR and CFR will be assessed using intra-coronary guidance;
- In the presence of CFR> 2.0 and IMR <25, tests with acetylcholine will also be performed in order to evaluate the possible presence of epicardial (focal or diffuse) or microvascular spasm.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cardiac Ischemia | Other: not required | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 200 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry" |
| Actual Study Start Date : | December 1, 2021 |
| Estimated Primary Completion Date : | November 15, 2022 |
| Estimated Study Completion Date : | April 1, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
assessment of coronary physiology
This is a prospective, multicentric, non-randomized , single-arm , open label clinical study. Included patients will be studied with invasive functional tests performed during index coronary angiography. These will include FFR, instantaneous Wave-Free Ratio (iFR), Resting Ful-Cycle Ra-tio (RFR), CFR, IMR and provocative Acetylcholine test. After the diagnosis of vasospastic angina (VSA) or coronary microvascular dysfunction (CMD) is made, a stratified medical therapy will then be initiated according to the results of physiological assessment according to ESC guidelines and recent EAPCI expert consensus document . |
Other: not required
This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms |
- investigate the prevalence of INOCA in women vs. men [ Time Frame: 3 year ]1. To investigate the prevalence of INOCA in women vs. men who are referred for a clinically indicated coronary angiography in three Centers in North-ern, Central and Southern Italy;
- stratify in INOCA endotypes patients [ Time Frame: 1 day (during physiology tests) ]2. to stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests
- implement a stratified therapy [ Time Frame: 1 year ]3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 1 year follow up
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical presentation of chronic ischemic heart disease (IHD), requiring coronary angiography for the diagnosis
- Absence of obstructive CAD at coronary angiography
- Age > 18 years
- Ability to provide a valid informed consent to the study procedure at the time of baseline evaluation
Exclusion Criteria:
- Clinical presentation of acute coronary syndrome (ACS) or cardiogenic shock
- Presence of obstructive CAD with at least 1 significant coronary artery stenosis, defined as diameter stenosis >50% and FFR ≤0.80 (or iFR/RFR ≤0.89)
- Previous coronary artery bypass grafting (CABG)
- Left ventricular systolic dysfunction, defined as ejection fraction (EF) <40%
- Severe valvular heart disease
- Pregnant or breastfeeding women
- Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (adenosine, nitrates, acetylcholine)
- Inability or unwillingness to provide a valid informed consent to the study procedure at the time of baseline evaluation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05164640
| Contact: Alaide Chieffo, MD | +39/02/2643/7331 ext 7362 | chieffo.alaide@hsr.it | |
| Contact: Vega Rusconi, no | +39/02/2643/7331 ext 7338 | rusconi.vega@hsr.it |
| Italy | |
| San Raffaele Hospital | Recruiting |
| Milan, Italy, 20132 | |
| Contact: Alaide Chieffo, MD +39/02/26437331 ext 7362 chieffo.alaide@hsr.it | |
| Contact: Marco Ancona, MD +39/02/26437331 ancona.marco@hsr.it | |
| Azienda Ospedaliera Universitaria Federico II, | Not yet recruiting |
| Napoli, Italy, 80131 | |
| Contact: Giovanni Esposito, MD +390817463075 espogiov@unina.it | |
| Contact: alessandra spinelli, BSC +390817462274 alessandra.spinelli@unina.it | |
| Sub-Investigator: Anna Franzone, MD | |
| Sub-Investigator: Raffaele Piccolo, MD | |
| Sub-Investigator: Luigi Di Serafino, MD | |
| Sub-Investigator: Giuseppe Gargiulo, MD | |
| Fondazione Policlinico Universitario A. Gemelli IRCCS, | Recruiting |
| Roma, Italy, 00168 | |
| Contact: Giampaolo Niccoli, MD +39/333 459 8964 gniccoli73@hotmail.it | |
| Contact: Domenico Galante, MD +393470635101 domenico.galante1991@gmail.com | |
| Sub-Investigator: Antonio MA Leone, MD | |
| Principal Investigator: | Alaide Chieffo, MD | IRCCS San Raffaele |
| Responsible Party: | Chieffo Alaide, Interventional cardiologist, IRCCS San Raffaele |
| ClinicalTrials.gov Identifier: | NCT05164640 |
| Other Study ID Numbers: |
RF-2019-12369486 |
| First Posted: | December 21, 2021 Key Record Dates |
| Last Update Posted: | February 10, 2022 |
| Last Verified: | February 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
non-obstructive coronary artery disease |
|
Coronary Artery Disease Myocardial Ischemia Ischemia Pathologic Processes Coronary Disease |
Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |